PeptideStack
5.2kquestions
20kanswers
220users

Why did two GGPeps lots of survodutide differ on content assay?

Asked 1 Jun 2024Modified 22 months agoViewed 64k times
37

The particulars: GGPeps · survodutide.

An unexpected observation, and I would like a differential rather than reassurance.

The conditions were within what I understood to be the acceptable range, which is why I am asking.

What is the most likely explanation, and how would I confirm it?

batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

865 questions
content-assay
content-assay

Quantified content: how many milligrams of peptide are actually in the vial, measured against a calibrated reference standard. A separate test…

438 questions
vendor-vetting
vendor-vetting

Evaluating a supplier on evidence rather than reputation: testing history across batches, whether certificates are batch-specific, how failures…

436 questions
shareeditfollowflag
M1
askedmass_shift_1814k181 Jun 2024

5 Answers

Accepted answer first, then by votes
-3

Accepted answer

Concretely, thermal history during shipping is different for every vial, so a lot that experienced thermal abuse may have internal variation even if it was originally homogeneous.

The sample size determination requires choosing a confidence level and an acceptable error rate, and the smaller the error rate you want, the larger your sample must be.

The relevant detail is that published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.

Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

shareimprove this answerflag
HV
answered · acceptedh_villanueva50k3810 Sept 2024
Sponsored

Janoshik Analytical - Independent Third-Party Testing

HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.

Submit a sample
Sponsored — paired listing

GL Biochem (Shanghai) Ltd. - Direct Synthesis

Founded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.

Visit GL Biochem
72

The practical consequence is that spot-testing one vial from a new supplier is better than assuming they are all the same.

For a quantitative result like content, the acceptable range determines how many vials you need to test to establish the lot complies.

If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.

I would treat a "complies with" statement without sampling details as a claim rather than as evidence.

Assume segregation is possible, and design your sampling to catch it if it exists.

shareimprove this answerflag
DV
answereddead_volume49k384 Jun 2024
49

Mechanically, batch testing establishes what can be claimed about the lot as a whole, and the sample size determines how much you can actually claim.

The statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.

The relevant detail is that if the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.

Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.

If testing multiple vials, state how many you tested and why you chose those vials.

edited 14 Oct 2024 by cold_lane — added the method parameters

shareimprove this answerflag
CL
answeredcold_lane14k1821 Sept 2024
29

The honest statement is that unless you have tested multiple vials or have segregation data, you are making an assumption about lot homogeneity that may not hold.

Stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.

Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.

One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

shareimprove this answerflag
M4
answeredmz_411399k25830 Aug 2024
2I would add a sentence about sterility here, since it is the thing people skip. – w_okoye 5 months ago
The placebo-arm figure is the part everyone omits. – retest_please 3 months ago
add a comment
22

Most suppliers test one vial per lot and report the result as lot homogeneity, which is sampling one item from one lot and extrapolating wildly.

Testing a vial that has been open in the lab for three months is testing aged material, not the fresh lot, and the result should be explicitly noted as a retest.

Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.

The caveat is that sampling is a trade-off between cost and confidence, and neither test nor assumption is cost-free.

Assume segregation is possible, and design your sampling to catch it if it exists.

shareimprove this answerflag
MO
answeredmarta_okonkwo87k25819 Jul 2024

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.